Tuesday, 24 September 2013

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies

Vipidia (alogliptin) and Fixed-Dose Combinations Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone)

Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes

Two pooled analyses of data from clinical trials in adults with type 2 diabetes, including the elderly with normal renal function to severe renal impairment, found similar incidence of adverse events for linagliptin compared with placebo (Lilly)

The association between dietary patterns and type 2 diabetes: a systematic review and meta-analysis of cohort studies

The results of this systematic review and meta-analysis indicate that dietary patterns may be associated with the risk of type 2 diabetes (Journal of Human Nutrition and Dietetics)

No comments:

Post a Comment